This page respects the original work's rights terms and independently introduces its bibliography, abstract, main results, and limitations. It is not a full translation.
About this resource
This page is a detailed introduction to the observational study by Brown and Alper, based on the structured abstract indexed in PubMed and publicly available bibliographic information. It is not a translation reconstructing the publisher’s full text. It presents the population, assessment times, and numerical results reported in the abstract, while distinguishing directly observed findings from the authors’ conclusions.
The study involved 30 people with DSM-IV opioid dependence who underwent ibogaine detoxification. It was a retrospective observational study without a comparison group, not a trial establishing causal efficacy or safety. This resource likewise does not provide diagnosis, treatment selection, or administration instructions, and its results cannot be applied to an individual.
Study design
The sample comprised 25 men and 5 women, for a total of 30 participants. The mean total amount of ibogaine hydrochloride received was reported as 1,540 ± 920 mg. Twenty-one participants (70%) used oxycodone and 18 (60%) used heroin; because the report says “and/or,” these groups may overlap. The respective amounts used were 250 ± 180 mg/day and 1.3 ± 0.94 g/day, and participants had undergone a mean of 3.1 ± 2.6 prior treatments for opioid dependence.
Acute withdrawal was assessed with the Subjective Opioid Withdrawal Scale (SOWS), and long-term outcomes with the domains of the Addiction Severity Index Composite (ASIC). Follow-up occurred at 1, 3, 6, 9, and 12 months after treatment. SOWS is a participant-reported withdrawal scale, and ASIC represents drug use, legal status, family and social relationships, and other domains as composite scores. The abstract does not describe a control group, randomization, or blinding.
Content
In their background, the authors state that ibogaine had been used for opioid use disorder in both medical and nonmedical settings, while no published study had prospectively examined drug-use outcomes. Their purpose was to observe withdrawal and drug-use outcomes after ibogaine detoxification for opioid dependence.
In the acute comparison reported in the abstract, mean SOWS decreased from 31.0 ± 11.6 before treatment to 14.0 ± 9.8 at 76.5 ± 30 hours afterward. The paired test yielded t = 7.07, 26 degrees of freedom, and p < 0.001. The 26 degrees of freedom suggest that paired data were not available for all 30 participants, but the public abstract does not explain the reason for missingness or identify the participants, so this resource does not speculate.
At one month, 15 participants—50% of everyone enrolled—self-reported no opioid use in the preceding 30 days. This is a self-report at the one-month point; it does not mean that the same 15 people remained opioid-free for 12 months. ASIC scores for drug use, legal status, and family/social status changed in the direction of improvement at every follow-up compared with pretreatment; the abstract reports p < 0.001. The change in drug-use score was greatest at one month. Improvement remained in the same direction at 3–12 months, but did not reach the magnitude seen at one month.
These are the observations that can be confirmed from the public abstract. The authors interpreted ibogaine as being associated with substantial changes in withdrawal symptoms and drug use among people for whom other treatments had failed, and as a possible prototype for exploring new addiction pharmacotherapies. This is the authors’ conclusion, not causal inference from a controlled trial. An observed association must be distinguished from the assertion that ibogaine caused the change.
Results
The principal numerical findings were a decrease in SOWS from 31.0 to 14.0, self-reported opioid nonuse during the preceding 30 days by 15 of 30 participants at one month, and improvement from baseline across three ASIC domains at each time point from 1 to 12 months. For the long-term drug-use score, the magnitude of change peaked at one month and then diminished.
The article did not establish superiority over standard treatment, a continuous 12-month abstinence rate, prevention of relapse, or safety including deaths and serious events. The abstract also does not describe objective confirmation of nonuse through urine testing or similar measures. Its findings cannot be reframed as “50% were cured” or “half remained abstinent for one year.”
Limitations
The sample was small at 30 participants, and the study was retrospective, observational, and uncontrolled. From the public abstract alone, it is not possible to determine how participants were selected, how many were lost to follow-up, or how many contributed data at each follow-up. The population was described as people for whom prior treatment had been unsuccessful, which also narrows applicability to the broader population with opioid use disorder.
SOWS, drug use, and reports of nonuse all include self-report and may be influenced by expectation, memory, and reporting bias. The effects of hospitalization, psychosocial support, other care, and natural history cannot be separated from those of ibogaine alone. The abstract does not provide denominators at each follow-up, handling of missing data, covariates, or detailed statistical procedures, so this introduction does not supply them. Dose variation was also substantial, and a mean alone does not reveal individual exposure or response.
Safety
The public PubMed abstract does not report adverse events, ECG changes, deaths, serious adverse events, exclusion criteria, concomitant medications, or methods of safety monitoring. It therefore cannot support a conclusion that “there were no adverse events” or “this dose was safe.” Improvement in withdrawal scores and drug-use outcomes is separate from evidence of safety. The reported mean amount is not a dosing recommendation and does not support use outside medical monitoring.
Source and rights
Bibliographic information and the abstract are available through PubMed, and the original article is identified by its DOI. The DOI metadata registered by the publisher with Crossref identifies the version of record as Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 (CC BY-NC-ND 4.0). This page is an independent detailed introduction based on the public abstract and metadata, not a translation or reconstruction of the publisher’s full text.